| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.
|
N Engl J Med
|
2013
|
5.22
|
|
2
|
Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies.
|
Circulation
|
2010
|
2.85
|
|
3
|
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
|
Circulation
|
2012
|
2.54
|
|
4
|
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
|
BMJ
|
2009
|
2.42
|
|
5
|
Mechanisms of disease: pulmonary arterial hypertension.
|
Nat Rev Cardiol
|
2011
|
2.39
|
|
6
|
Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension.
|
Circulation
|
2008
|
2.18
|
|
7
|
Two binding sites for [3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation.
|
J Cereb Blood Flow Metab
|
2010
|
1.85
|
|
8
|
Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension.
|
Circulation
|
2005
|
1.62
|
|
9
|
Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension.
|
Circulation
|
2003
|
1.57
|
|
10
|
Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.
|
Am J Respir Crit Care Med
|
2005
|
1.56
|
|
11
|
Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights.
|
J Am Coll Cardiol
|
2011
|
1.48
|
|
12
|
Recent insights into the pathogenesis and therapeutics of pulmonary hypertension.
|
Clin Sci (Lond)
|
2002
|
1.46
|
|
13
|
Emerging concepts and translational priorities in pulmonary arterial hypertension.
|
Circulation
|
2008
|
1.39
|
|
14
|
Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension.
|
Br J Clin Pharmacol
|
2005
|
1.29
|
|
15
|
Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension.
|
Hum Mutat
|
2011
|
1.18
|
|
16
|
Proteomic analysis of lung tissues from patients with pulmonary arterial hypertension.
|
Circulation
|
2010
|
1.16
|
|
17
|
Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension.
|
Am J Respir Crit Care Med
|
2008
|
1.12
|
|
18
|
Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension.
|
Am J Respir Crit Care Med
|
2012
|
1.11
|
|
19
|
Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension.
|
Heart
|
2011
|
1.09
|
|
20
|
5-Hydroxytryptamine1A receptor occupancy by novel full antagonist 2-[4-[4-(7-chloro-2,3-dihydro-1,4-benzdioxyn-5-yl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3-(2H)-one-1,1-dioxide: a[11C][O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide trihydrochloride (WAY-100635) positron emission tomography study in humans.
|
J Pharmacol Exp Ther
|
2002
|
1.04
|
|
21
|
Genetic association of the serotonin transporter in pulmonary arterial hypertension.
|
Am J Respir Crit Care Med
|
2006
|
1.01
|
|
22
|
Role of RhoB in the regulation of pulmonary endothelial and smooth muscle cell responses to hypoxia.
|
Circ Res
|
2012
|
1.01
|
|
23
|
Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity.
|
Circulation
|
2003
|
1.00
|
|
24
|
cAMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling.
|
Am J Physiol Lung Cell Mol Physiol
|
2004
|
1.00
|
|
25
|
Atorvastatin in pulmonary arterial hypertension (APATH) study.
|
Eur Respir J
|
2012
|
0.98
|
|
26
|
Therapeutic targets in pulmonary arterial hypertension.
|
Pharmacol Ther
|
2008
|
0.97
|
|
27
|
Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments.
|
Circulation
|
2013
|
0.95
|
|
28
|
Variation in binding affinity of the novel anxiolytic XBD173 for the 18 kDa translocator protein in human brain.
|
Synapse
|
2011
|
0.95
|
|
29
|
A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers.
|
PLoS One
|
2012
|
0.94
|
|
30
|
Synergy between natriuretic peptides and phosphodiesterase 5 inhibitors ameliorates pulmonary arterial hypertension.
|
Am J Respir Crit Care Med
|
2008
|
0.93
|
|
31
|
Identification of plasma protein biomarkers associated with idiopathic pulmonary arterial hypertension.
|
Proteomics
|
2006
|
0.91
|
|
32
|
Characterization of high-altitude pulmonary hypertension in the Kyrgyz: association with angiotensin-converting enzyme genotype.
|
Am J Respir Crit Care Med
|
2002
|
0.91
|
|
33
|
Differences in ventilatory inefficiency between pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
|
Chest
|
2011
|
0.88
|
|
34
|
Safety of sapropterin dihydrochloride (6r-bh4) in patients with pulmonary hypertension.
|
Exp Lung Res
|
2010
|
0.86
|
|
35
|
Comparison of 18F-FDG uptake by right ventricular myocardium in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with congenital heart disease.
|
Pulm Circ
|
2012
|
0.86
|
|
36
|
Supplementation of iron in pulmonary hypertension: Rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension.
|
Pulm Circ
|
2013
|
0.85
|
|
37
|
Advancing clinical trial design in pulmonary hypertension.
|
Pulm Circ
|
2013
|
0.84
|
|
38
|
Aberrant chloride intracellular channel 4 expression contributes to endothelial dysfunction in pulmonary arterial hypertension.
|
Circulation
|
2014
|
0.84
|
|
39
|
Endothelial progenitor cells in pulmonary arterial hypertension.
|
Trends Cardiovasc Med
|
2010
|
0.84
|
|
40
|
Genome-wide scan for premature hypertension supports linkage to chromosome 2 in a large Kyrgyz family.
|
Hypertension
|
2006
|
0.82
|
|
41
|
Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11C]WAY-100635 and [11C]raclopride.
|
J Psychopharmacol
|
2002
|
0.82
|
|
42
|
Identification and assessment of plasma lysozyme as a putative biomarker of atherosclerosis.
|
Arterioscler Thromb Vasc Biol
|
2010
|
0.80
|
|
43
|
Clinical, ethical and financial implications of incidental imaging findings: experience from a phase I trial in healthy elderly volunteers.
|
PLoS One
|
2012
|
0.80
|
|
44
|
Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension.
|
Rheumatology (Oxford)
|
2013
|
0.79
|
|
45
|
Regulating cell-based regenerative medicine: the challenges ahead.
|
Regen Med
|
2014
|
0.78
|
|
46
|
Pulmonary hypertension: biomarkers.
|
Handb Exp Pharmacol
|
2013
|
0.78
|
|
47
|
Cannabis and cannabis-based medicines: potential benefits and risks to health.
|
Clin Med
|
2006
|
0.78
|
|
48
|
[Definitions and diagnosis of pulmonary hypertension].
|
Turk Kardiyol Dern Ars
|
2014
|
0.77
|
|
49
|
Pulmonary hypertension: old targets revisited (statins, PPARs, beta-blockers).
|
Handb Exp Pharmacol
|
2013
|
0.76
|
|
50
|
Pulmonary arterial hypertension and the vasoconstrictive factor: is there still a role for vasodilator testing?
|
Eur Heart J
|
2003
|
0.76
|
|
51
|
Role of asymmetric methylarginine and connexin 43 in the regulation of pulmonary endothelial function.
|
Pulm Circ
|
2013
|
0.76
|
|
52
|
The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects.
|
Br J Clin Pharmacol
|
2010
|
0.75
|
|
53
|
Selective or nonselective endothelin receptor blockade in pulmonary arterial hypertension.
|
Am J Respir Crit Care Med
|
2004
|
0.75
|
|
54
|
Response to letter regarding article, “histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid”.
|
Circulation
|
2013
|
0.75
|